Literature DB >> 19941709

Confirmation of ureteric patency during cystoscopy using phenazopyridine HCl: a low-cost approach.

Jane Y C Hui1, Marie-Andrée Harvey1, Shawna L Johnston1.   

Abstract

OBJECTIVE: To describe the use of oral phenazopyridine (Pyridium) prior to pelvic surgery to facilitate intraoperative confirmation of ureteric patency.
MATERIALS AND METHODS: We performed a chart review of women given phenazopyridine preoperatively prior to pelvic surgery in a tertiary care centre between July 2004 and June 2005. The primary outcome was the cystoscopic observation of bilateral ureteric urine efflux. Secondary outcomes included the visualization of bladder mucosa during cystoscopy, postoperative complications, and urinary tract injury diagnosed postoperatively (i.e., missed intraoperatively).
RESULTS: Pelvic reconstructive surgery requiring intraoperative cystoscopy was performed in 124 women. Bilateral ureteric patency and bladder mucosal integrity was confirmed in all cases. Phenazopyridine was well tolerated by all patients, and its use was unequivocally documented in 32 subjects whose chart was reviewed to determine postoperative course. Bladder mucosal appearance was unaltered. Dye continued to be excreted during prolonged procedures. Postoperatively, no ureteric injuries were subsequently diagnosed in any patients. The cost per patient of phenazopyridine ($0.29) is substantially lower than indigo carmine ($34.50).
CONCLUSION: Preoperative oral phenazopyridine is an inexpensive and safe dye that assists effectively in the confirmation of ureteric patency when cystoscopy is planned during pelvic surgery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19941709     DOI: 10.1016/S1701-2163(16)34303-1

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  1 in total

1.  Effectiveness of Assessing Ureteral Patency Using Preoperative Phenazopyridine.

Authors:  Elizabeth M Strom; Zaid Q Chaudhry; Rong Guo; Axeline J Maisonet; Christine H Holschneider; Cecilia K Wieslander
Journal:  Female Pelvic Med Reconstr Surg       Date:  2019 Jul/Aug       Impact factor: 2.091

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.